HF
NAVB

HRT Financial’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

HRT Financial’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,614
Closed -$2K – 3626
2022
Q4 		$2K Buy
+12,614
New +$3.15K ﹤0.01% 2364

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HRT Financial's NAVB Position: Q1 2023 in Review

HRT Financial sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2023, closing a stake of 12,614 shares — an estimated $2K sold.

HRT Financial first reported a position in NAVB in Q4 2022 and held it in 1 quarter. The position peaked at $2K in Q4 2022. 30 funds tracked by Wall St. Rank hold NAVB as of Q1 2023.

  • HRT Financial reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2023 after selling out during the quarter.
  • HRT Financial sold 12,614 Navidea Biopharmaceuticals Inc. shares in Q1 2023, an estimated $2K.
  • HRT Financial first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2022 and held it in 1 quarter.
  • HRT Financial's Navidea Biopharmaceuticals Inc. position peaked at $2K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.